NEW YORK, Feb. 21 (GenomeWeb News) - Inpharmatica said today that it has licensed its Admensa Interactive suite of predictive drug absorption, distribution, metabolism, and excretion models and compound prioritization tools to biotech firm Serono.
Under the terms of the non-exclusive deal, Serono will receive a multi-site license to the Admensa technology, as well as training and ADME consulting. Additional terms were not disclosed.
The licensing deal builds on the companies' existing collaboration to identify and develop protein therapeutics.